251 related articles for article (PubMed ID: 19181962)
1. Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis.
Kroll J; Epting D; Kern K; Dietz CT; Feng Y; Hammes HP; Wieland T; Augustin HG
Am J Physiol Heart Circ Physiol; 2009 Mar; 296(3):H893-9. PubMed ID: 19181962
[TBL] [Abstract][Full Text] [Related]
2. Fasudil-induced hypoxia-inducible factor-1alpha degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells.
Takata K; Morishige K; Takahashi T; Hashimoto K; Tsutsumi S; Yin L; Ohta T; Kawagoe J; Takahashi K; Kurachi H
Mol Cancer Ther; 2008 Jun; 7(6):1551-61. PubMed ID: 18566226
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic properties of fasudil, a potent Rho-Kinase inhibitor.
Hata Y; Miura M; Nakao S; Kawahara S; Kita T; Ishibashi T
Jpn J Ophthalmol; 2008; 52(1):16-23. PubMed ID: 18369695
[TBL] [Abstract][Full Text] [Related]
4. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo.
Yin L; Morishige K; Takahashi T; Hashimoto K; Ogata S; Tsutsumi S; Takata K; Ohta T; Kawagoe J; Takahashi K; Kurachi H
Mol Cancer Ther; 2007 May; 6(5):1517-25. PubMed ID: 17513600
[TBL] [Abstract][Full Text] [Related]
5. Cdc42 and RhoA have opposing roles in regulating membrane type 1-matrix metalloproteinase localization and matrix metalloproteinase-2 activation.
Ispanovic E; Serio D; Haas TL
Am J Physiol Cell Physiol; 2008 Sep; 295(3):C600-10. PubMed ID: 18562481
[TBL] [Abstract][Full Text] [Related]
6. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
Sini P; Wyder L; Schnell C; O'Reilly T; Littlewood A; Brandt R; Hynes NE; Wood J
Clin Cancer Res; 2005 Jun; 11(12):4521-32. PubMed ID: 15958638
[TBL] [Abstract][Full Text] [Related]
7. VEGF-Induced Endothelial Podosomes via ROCK2-Dependent Thrombomodulin Expression Initiate Sprouting Angiogenesis.
Kuo CH; Huang YH; Chen PK; Lee GH; Tang MJ; Conway EM; Shi GY; Wu HL
Arterioscler Thromb Vasc Biol; 2021 May; 41(5):1657-1671. PubMed ID: 33730876
[TBL] [Abstract][Full Text] [Related]
8. RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis.
Bryan BA; Dennstedt E; Mitchell DC; Walshe TE; Noma K; Loureiro R; Saint-Geniez M; Campaigniac JP; Liao JK; D'Amore PA
FASEB J; 2010 Sep; 24(9):3186-95. PubMed ID: 20400538
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase C alpha promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor.
Xu H; Czerwinski P; Hortmann M; Sohn HY; Förstermann U; Li H
Cardiovasc Res; 2008 May; 78(2):349-55. PubMed ID: 18056764
[TBL] [Abstract][Full Text] [Related]
10. Isoprostanes inhibit vascular endothelial growth factor-induced endothelial cell migration, tube formation, and cardiac vessel sprouting in vitro, as well as angiogenesis in vivo via activation of the thromboxane A(2) receptor: a potential link between oxidative stress and impaired angiogenesis.
Benndorf RA; Schwedhelm E; Gnann A; Taheri R; Kom G; Didié M; Steenpass A; Ergün S; Böger RH
Circ Res; 2008 Oct; 103(9):1037-46. PubMed ID: 18802021
[TBL] [Abstract][Full Text] [Related]
11. Activation of fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia.
Ryu J; Lee CW; Hong KH; Shin JA; Lim SH; Park CS; Shim J; Nam KB; Choi KJ; Kim YH; Han KH
Cardiovasc Res; 2008 May; 78(2):333-40. PubMed ID: 18006432
[TBL] [Abstract][Full Text] [Related]
12. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
13. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation.
Buharalioglu CK; Song CY; Yaghini FA; Ghafoor HU; Motiwala M; Adris T; Estes AM; Malik KU
Am J Physiol Heart Circ Physiol; 2011 Sep; 301(3):H1043-55. PubMed ID: 21642504
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
16. Afadin Facilitates Vascular Endothelial Growth Factor-Induced Network Formation and Migration of Vascular Endothelial Cells by Inactivating Rho-Associated Kinase Through ArhGAP29.
Tagashira T; Fukuda T; Miyata M; Nakamura K; Fujita H; Takai Y; Hirata KI; Rikitake Y
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1159-1169. PubMed ID: 29599137
[TBL] [Abstract][Full Text] [Related]
17. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the Rho/Rho kinase signaling pathway in platelet-derived growth factor BB-induced vascular endothelial growth factor expression in diabetic rat retina.
Yokota T; Utsunomiya K; Taniguchi K; Gojo A; Kurata H; Tajima N
Jpn J Ophthalmol; 2007; 51(6):424-30. PubMed ID: 18158592
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium.
Carbajo-Lozoya J; Lutz S; Feng Y; Kroll J; Hammes HP; Wieland T
Cell Signal; 2012 Jun; 24(6):1261-9. PubMed ID: 22374305
[TBL] [Abstract][Full Text] [Related]
20. HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways.
Nakabayashi H; Shimizu K
Cancer Sci; 2011 Feb; 102(2):393-9. PubMed ID: 21166955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
